| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $0 | -100.0% |
| R&D Expense | $17.2M | +26.4% |
| SG&A Expense | $11.4M | +69.0% |
| Operating Income | -$28.6M | -42.3% |
| Net Income | -$27.5M | -44.6% |
| EPS (Basic) | -$1.16 | +67.5% |
| EPS (Diluted) | -$1.16 | +67.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $56.5M | +516.1% |
| Short-term Investments | $41.1M | +904.5% |
| Current Assets | $98.5M | +592.8% |
| Total Assets | $98.6M | +579.7% |
| Current Liabilities | $3.7M | +8.6% |
| Total Liabilities | $3.7M | +5.8% |
| Stockholders' Equity | $94.9M | +764.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$19.1M | -5.9% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | -$37.0M | -417.5% |
| Financing Cash Flow | $103.5M | +1131.1% |
| Free Cash Flow | -$19.1M | -5.8% |